Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Choosing Wisely: Recommendations from Medical Specialties Beyond Rheumatology

Kurt Ullman  |  Issue: October 2014  |  October 1, 2014

“The other thing I would point out is that CW also brings home the point that we shouldn’t be ordering unproven diagnostic tests,” says Dr. King. “We need to think about pretest probabilities and how a test will help diagnostically instead of just ticking off a box on a computer’s order list. Often, tests are ordered as screening tests instead of in response to clinical indicators.”

Rheumatology’s Strong Suit

If anything, the consensus of the experts is that the concept of Choosing Wisely leads to what has always been a strong suit of the rheumatologist.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“These all call for a good history and physical exam, which we are very adept at doing, as an entry point to proper patient management,” says Dr. Saag. “Taking a careful history and an appropriate physical examination that then leads to doing the simple things before moving on to the more expensive tests will provide needed answers at lower costs.”

As the healthcare system changes, there will be a growing focus on how and when the more expensive interventions are used. This is a continuation of Dr. Saag’s discussion of the change in emphasis from underutilization to overutilization.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“This is a way for societies to begin to police themselves and maybe stop doing things just because they are easy,” he says. “In an era of worry about the tremendous costs of healthcare, it is incumbent on us all to do the best we can for our patients, but also be aware of the costs.”

travellight/shutterstock.com

Impact on Clinical Decision Making?

Each time one of the CW lists is released, concerns have been voiced about taking away some of a physician’s ability to make decisions based on the patient they see in front of them. CW’s website stresses that the recommendations “are meant to spur conversation about what is appropriate and necessary treatment. As [sic] each patient situation is unique, providers and patients should use the recommendations as guidelines to determine an appropriate treatment plan together.”

“The recommendations made by each society’s CW list are meant to foster communication between patients and providers,” says Dr. King. “They are not meant to be proscriptive. Ultimately, the decision to order a certain test or treatment rests with the provider.”

There is also agreement that the healthcare system of the future is one in which physicians communicate with each other across multiple specialties and areas of expertise. This will require increasing cooperation and coordination around common areas in guidelines and clinical recommendations.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Drug UpdatesPractice SupportQuality Assurance/Improvement Tagged with:AC&RAmerican College of Rheumatology (ACR)BiologicscostsdrugimagingrheumatologistSafetyUllman

Related Articles

    Diagnostic Criteria Released for Neuromyelitis Optica Spectrum Disorders

    November 16, 2015

    Recent updates to criteria used for diagnosing neuromyelitis optica (NMO) are aimed at helping physicians make the differential diagnosis of this disorder differentiating it from other inflammatory disorders—a diagnosis that can be difficult given the presenting symptoms that can mimic a number of other conditions, such as multiple sclerosis. Published in July 2015, the new…

    Best Practices for Treating Non-Specific Low Back Pain

    December 16, 2015

    Low back pain (LBP) is one of the most common reasons for physician appointments. However, treatment results remain suboptimal, resulting in high rates of chronic pain, narcotic usage, surgery, depression and disability—all at great cost to individuals and the nation. One reason for this is the current practice of grouping all low back pain patients…

    Corona Borealis Studio / shutterstock.com

    The Reliability & Utility of Serological Antibody Tests in COVID-19

    September 11, 2020

    Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may play a critical role in the management of the worldwide health crisis. Such testing may reveal key information for epidemiology, convalescent plasma therapies and vaccine development. However, the situation is complex, and much is unknown. Although such testing may ultimately be used to…

    Serological Antibody Tests in COVID-19: Test Reliability and Utility

    June 10, 2020

    Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may play a critical role in the management of the worldwide health crisis. Such testing may reveal key information for epidemiology, convalescent plasma therapies and vaccine development. However, the situation is complex, and much is unknown. Although such testing may ultimately be used to…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences